Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 73

1.

Development of a clinician questionnaire and patient interview to assess reasons for antipsychotic discontinuation.

Matza LS, Phillips GA, Revicki DA, Ascher-Svanum H, Kaiser D, Stauffer V, Shorr JM, Kinon BJ.

Psychiatry Res. 2011 Oct 30;189(3):463-8. doi: 10.1016/j.psychres.2011.05.030. Epub 2011 Jun 17.

PMID:
21684017
2.

Construct validity of 2 measures to assess reasons for antipsychotic discontinuation and continuation from patients' and clinicians' perspectives in a clinical trial.

Faries D, Ascher-Svanum H, Phillips G, Nyhuis AW, Sugihara T, Stauffer V, Kinon BJ.

BMC Med Res Methodol. 2012 Sep 13;12:142. doi: 10.1186/1471-2288-12-142.

3.

Validation of a clinician questionnaire to assess reasons for antipsychotic discontinuation and continuation among patients with schizophrenia.

Matza LS, Phillips GA, Revicki DA, Ascher-Svanum H, Malley KG, Palsgrove AC, Faries DE, Stauffer V, Kinon BJ, George Awad A, Keefe RS, Naber D.

Psychiatry Res. 2012 Dec 30;200(2-3):835-42. doi: 10.1016/j.psychres.2012.05.005. Epub 2012 Jul 28.

PMID:
22841345
4.

Validation of a patient interview for assessing reasons for antipsychotic discontinuation and continuation.

Matza LS, Phillips GA, Revicki DA, Ascher-Svanum H, Malley KG, Palsgrove AC, Faries DE, Stauffer V, Kinon BJ, Awad AG, Keefe RS, Naber D.

Patient Prefer Adherence. 2012;6:521-32. doi: 10.2147/PPA.S25635. Epub 2012 Jul 13.

5.

Reasons for discontinuation and continuation of antipsychotics in the treatment of schizophrenia from patient and clinician perspectives.

Ascher-Svanum H, Nyhuis AW, Stauffer V, Kinon BJ, Faries DE, Phillips GA, Schuh K, Awad AG, Keefe R, Naber D.

Curr Med Res Opin. 2010 Oct;26(10):2403-10. doi: 10.1185/03007995.2010.515900.

PMID:
20812791
6.

Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment.

Lewis SW, Davies L, Jones PB, Barnes TR, Murray RM, Kerwin R, Taylor D, Hayhurst KP, Markwick A, Lloyd H, Dunn G.

Health Technol Assess. 2006 May;10(17):iii-iv, ix-xi, 1-165.

7.

Cocaine and amphetamine use in patients with psychiatric illness: a randomized trial of typical antipsychotic continuation or discontinuation.

Brown ES, Nejtek VA, Perantie DC, Rajan Thomas N, Rush AJ.

J Clin Psychopharmacol. 2003 Aug;23(4):384-8.

PMID:
12920415
8.

Using antipsychotic agents in older patients.

Alexopoulos GS, Streim J, Carpenter D, Docherty JP; Expert Consensus Panel for Using Antipsychotic Drugs in Older Patients.

J Clin Psychiatry. 2004;65 Suppl 2:5-99; discussion 100-102; quiz 103-4. Review.

9.

[Diagnostic structured interviews in child and adolescent's psychiatry].

Renou S, Hergueta T, Flament M, Mouren-Simeoni MC, Lecrubier Y.

Encephale. 2004 Mar-Apr;30(2):122-34. Review. French.

PMID:
15107714
10.

Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).

Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP, Murray RM, Markwick A, Lewis SW.

Arch Gen Psychiatry. 2006 Oct;63(10):1079-87.

PMID:
17015810
11.

[Relationships between insight and medication adherence in subjects with psychosis].

Droulout T, Liraud F, Verdoux H.

Encephale. 2003 Sep-Oct;29(5):430-7. French.

PMID:
14615692
12.
13.

Mood-stabilizer-maintained, remitted bipolar patients: taper and discontinuation of adjunctive antipsychotic medication.

Saksa JR, Baker CB, Woods SW.

Gen Hosp Psychiatry. 2004 May-Jun;26(3):233-6.

PMID:
15121352
14.

[Validation of the QFS measuring the frequency and satisfaction in social behaviours in psychiatric adult population].

Zanello A, Weber Rouget B, Gex-Fabry M, Maercker A, Guimon J.

Encephale. 2006 Jan-Feb;32(1 Pt 1):45-59. French.

PMID:
16633290
15.

The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary.

Kane JM, Leucht S, Carpenter D, Docherty JP; Expert Consensus Panel for Optimizing Pharmacologic Treatment of Psychotic Disorders.

J Clin Psychiatry. 2003;64 Suppl 12:5-19.

16.
17.

A comparison of clinician and patient concerns about antipsychotic side effects: a pilot study.

Huffman JC, Blais MA, Pirl WF.

J Nerv Ment Dis. 2004 Apr;192(4):328-30.

PMID:
15060409
18.

Comparison of patient and clinician perspectives in the assessment of antipsychotic medication adherence.

Barbui C, Kikkert M, Mazzi MA, Becker T, Bindman J, Schene A, Nosè M, Helm H, Thornicroft G, Tansella M.

Psychopathology. 2009;42(5):311-7. doi: 10.1159/000232973. Epub 2009 Aug 11.

PMID:
19672133
19.

A review of second-generation antipsychotic discontinuation in first-episode psychosis.

Miller BJ.

J Psychiatr Pract. 2008 Sep;14(5):289-300. doi: 10.1097/01.pra.0000336756.65308.83. Review.

PMID:
18832960
20.

Assessment of clinician awareness of nonadherence using a new structured rating scale.

Clayton CD, Veach J, Macfadden W, Haskins J, Docherty JP, Lindenmayer JP.

J Psychiatr Pract. 2010 May;16(3):164-9. doi: 10.1097/01.pra.0000375712.85454.c6.

PMID:
20485104

Supplemental Content

Support Center